title: Liraglutide therapy in Prader-Willi syndrome.
authors.forename: K
authors.initials: K
authors.lastname: Cyganek
authors.forename: T
authors.initials: T
authors.lastname: Koblik
authors.forename: E
authors.initials: E
authors.lastname: Kozek
authors.forename: M
authors.initials: M
authors.lastname: Wojcik
authors.forename: J
authors.initials: J
authors.lastname: Starzyk
authors.forename: M T
authors.initials: MT
authors.lastname: Malecki
mesh_terms: D000293:Adolescent; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D000069450:Liraglutide; D008687:Metformin / Q000627:therapeutic use*; D009767:Obesity, Morbid / Q000188:drug therapy* / Q000378:metabolism; D011218:Prader-Willi Syndrome / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D008687:Metformin